Prediction models for ischemic stroke and bleeding in dialysis patients: a systematic review and meta-analysis
- PMID: 39981320
- PMCID: PMC11841370
- DOI: 10.1093/ckj/sfae347
Prediction models for ischemic stroke and bleeding in dialysis patients: a systematic review and meta-analysis
Abstract
Background: Patients with kidney failure on maintenance dialysis have a high stroke and bleeding risk. Multivariable prediction models can be used to estimate the risk of ischemic stroke and bleeding. A systematic review and meta-analysis was performed to determine the performance of the existing models in patients on dialysis.
Methods: MEDLINE and Embase databases were searched, from inception through 12 January 2024, for studies of prediction models for stroke or bleeding, derived or validated in dialysis cohorts. Discrimination measures for models with c-statistic data from three or more cohorts were pooled by random effects meta-analysis and a 95% prediction interval (PI) was calculated. Risk of bias was assessed using PROBAST. The review was conducted according to the PRISMA statement and the CHARMS checklist.
Results: Eight studies were included in this systematic review. All the included studies validated pre-existing models that were derived in cohorts from the general population. None of the identified studies reported the development of a new dialysis specific prediction model for stroke, while dialysis specific risk scores for bleeding were proposed by two studies. In meta-analysis of c-statistics, the CHA2DS2-VASc, CHADS2, ATRIA, HEMORR(2)HAGES and HAS-BLED scores showed very poor discriminative ability in the dialysis population. Six of the eight included studies were at low or unclear risk of bias and certainty of evidence was moderate.
Conclusions: The existing prediction models for stroke and bleeding have very poor performance in the dialysis population. New dialysis-specific risk scores should be developed to guide clinical decision making in these patients.
Keywords: bleeding; dialysis; meta-analysis; prediction models; stroke.
© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.
Conflict of interest statement
T.A.M. has received speaker honoraria from Bayer, BMS Canada, Janssen, AstraZeneca and Pfizer; and has served on advisory boards for Boehringer Ingelheim, Bayer, GSK and Servier outside the submitted work. He has also received research grants from AstraZeneca and Pfizer. He is supported by a Fonds de Recherche Santé Quebec (FRSQ) Junior 1 Clinician Scholar award and a Kidney Research Scientist Core Education and National Training (KRESCENT) program New Investigator Award. E.T. has received speaker honorarium from Baxter Inc., investigator-initiated funding from Otsuka and GSK, and consulting fees from Otsuka. The remaining authors have no relevant disclosures.
Figures
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
